HRP20231241T1 - Upotreba sastava braf inhibitora za lokalnu primjenu za liječenje radijacijskog dermatitisa - Google Patents
Upotreba sastava braf inhibitora za lokalnu primjenu za liječenje radijacijskog dermatitisa Download PDFInfo
- Publication number
- HRP20231241T1 HRP20231241T1 HRP20231241TT HRP20231241T HRP20231241T1 HR P20231241 T1 HRP20231241 T1 HR P20231241T1 HR P20231241T T HRP20231241T T HR P20231241TT HR P20231241 T HRP20231241 T HR P20231241T HR P20231241 T1 HRP20231241 T1 HR P20231241T1
- Authority
- HR
- Croatia
- Prior art keywords
- grade
- composition
- use according
- rtog
- ctcae
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 18
- 230000000699 topical effect Effects 0.000 title claims 9
- 229940125431 BRAF inhibitor Drugs 0.000 title claims 6
- 208000006934 radiodermatitis Diseases 0.000 title claims 3
- -1 ARQ680 Chemical compound 0.000 claims 18
- 206010067484 Adverse reaction Diseases 0.000 claims 12
- 230000006838 adverse reaction Effects 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical group C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 2
- 229960002465 dabrafenib Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- MMNNTJYFHUDSKL-UHFFFAOYSA-N methyl n-[6-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxoisoindol-1-yl]-1h-benzimidazol-2-yl]carbamate Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(C1=CC=CC=C1C1=O)(O)N1C1=CC(Cl)=CC=C1C MMNNTJYFHUDSKL-UHFFFAOYSA-N 0.000 claims 2
- 101150009274 nhr-1 gene Proteins 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229960003787 sorafenib Drugs 0.000 claims 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 2
- 229960003862 vemurafenib Drugs 0.000 claims 2
- DKNUPRMJNUQNHR-UHFFFAOYSA-N 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC(C=1)=CC=CC=1NC(=O)NC=1C=C(C(C)(C)C(F)(F)F)ON=1 DKNUPRMJNUQNHR-UHFFFAOYSA-N 0.000 claims 1
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims 1
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 claims 1
- VWMJHAFYPMOMGF-ZCFIWIBFSA-N TAK-580 Chemical compound N([C@H](C)C=1SC(=CN=1)C(=O)NC=1N=CC(Cl)=C(C=1)C(F)(F)F)C(=O)C1=NC=NC(N)=C1Cl VWMJHAFYPMOMGF-ZCFIWIBFSA-N 0.000 claims 1
- OJFKUJDRGJSAQB-UHFFFAOYSA-N TAK-632 Chemical compound C1=C(NC(=O)CC=2C=C(C=CC=2)C(F)(F)F)C(F)=CC=C1OC(C(=C1S2)C#N)=CC=C1N=C2NC(=O)C1CC1 OJFKUJDRGJSAQB-UHFFFAOYSA-N 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000007933 dermal patch Substances 0.000 claims 1
- HXINDCTZKGGRDE-JPKZNVRTSA-L disodium;[3-[5-[2-[[(3r)-1-(1-methylpyrazol-3-yl)sulfonylpiperidin-3-yl]amino]pyrimidin-4-yl]imidazo[2,1-b][1,3]oxazol-6-yl]phenoxy]methyl phosphate Chemical compound [Na+].[Na+].CN1C=CC(S(=O)(=O)N2C[C@@H](CCC2)NC=2N=C(C=CN=2)C=2N3C=COC3=NC=2C=2C=C(OCOP([O-])([O-])=O)C=CC=2)=N1 HXINDCTZKGGRDE-JPKZNVRTSA-L 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962804235P | 2019-02-12 | 2019-02-12 | |
| EP20756229.9A EP3923911B1 (en) | 2019-02-12 | 2020-02-11 | Use of topical braf inhibitor compositions for treatment of radiation dermatitis |
| PCT/IB2020/051073 WO2020165755A1 (en) | 2019-02-12 | 2020-02-11 | Use of topical braf inhibitor compositions for treatment of radiation dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231241T1 true HRP20231241T1 (hr) | 2024-02-16 |
Family
ID=72044789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231241TT HRP20231241T1 (hr) | 2019-02-12 | 2020-02-11 | Upotreba sastava braf inhibitora za lokalnu primjenu za liječenje radijacijskog dermatitisa |
Country Status (17)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022136912A1 (en) * | 2020-12-24 | 2022-06-30 | Lutris Pharma Ltd. | Topical braf inhibitor compositions for treatment of egfr downstream effectors - induced reactions |
| WO2023275620A2 (en) * | 2021-07-02 | 2023-01-05 | Lutris Pharma Ltd. | Use of isoquinoline-1,5-diamines for wound healing |
| WO2023051685A1 (zh) * | 2021-09-30 | 2023-04-06 | 北京大学 | 一种对红系前体细胞或成红细胞进行扩增的方法及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753612A (en) | 1992-10-27 | 1998-05-19 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| US8557830B2 (en) | 2007-06-07 | 2013-10-15 | Amgen Inc. | RAF kinase modulators and methods of use |
| AU2009226136B2 (en) * | 2008-03-17 | 2013-08-15 | Ambit Biosciences Corporation | Quinazoline derivatives as RAF kinase modulators and methods of use thereof |
| US9290507B2 (en) * | 2010-03-26 | 2016-03-22 | Boehringer Ingelheim International Gmbh | B-RAF kinase inhibitors |
| TWI611053B (zh) | 2012-02-27 | 2018-01-11 | 曾宇鳳 | 為先導藥物最適化之以結構為基礎的片段遷越及合成可行性之改良 |
| KR20140011780A (ko) | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체 |
| CN106535900A (zh) * | 2014-05-06 | 2017-03-22 | 加利福尼亚大学董事会 | 使用braf抑制剂的伤口愈合 |
| CN109069511A (zh) | 2016-03-10 | 2018-12-21 | 鲁特里斯制药有限公司 | Braf抑制剂用于治疗皮肤反应的用途 |
| SI3661515T1 (sl) * | 2017-07-29 | 2022-06-30 | Lutris Pharma Ltd. | Novi BRaf inhibitorji in njihova uporaba za zadravljenje kožnih reakcij |
| US11458139B2 (en) * | 2017-08-08 | 2022-10-04 | Memorial Sloan Kettering Cancer Center | Use of BRAF inhibitors for treating cutaneous reactions caused by treatment with a MEK inhibitor |
-
2020
- 2020-02-11 MX MX2021009535A patent/MX2021009535A/es unknown
- 2020-02-11 PL PL20756229.9T patent/PL3923911T3/pl unknown
- 2020-02-11 BR BR112021015137-0A patent/BR112021015137A2/pt unknown
- 2020-02-11 HU HUE20756229A patent/HUE063091T2/hu unknown
- 2020-02-11 HR HRP20231241TT patent/HRP20231241T1/hr unknown
- 2020-02-11 CA CA3127175A patent/CA3127175C/en active Active
- 2020-02-11 KR KR1020217029012A patent/KR102534457B1/ko active Active
- 2020-02-11 EP EP20756229.9A patent/EP3923911B1/en active Active
- 2020-02-11 JP JP2021545958A patent/JP2022519675A/ja active Pending
- 2020-02-11 AU AU2020220895A patent/AU2020220895B9/en active Active
- 2020-02-11 ES ES20756229T patent/ES2952251T3/es active Active
- 2020-02-11 CN CN202080012207.4A patent/CN113382717A/zh active Pending
- 2020-02-11 WO PCT/IB2020/051073 patent/WO2020165755A1/en not_active Ceased
- 2020-02-11 RS RS20230855A patent/RS64618B1/sr unknown
- 2020-02-11 IL IL285560A patent/IL285560B2/en unknown
-
2021
- 2021-07-23 US US17/384,221 patent/US11439648B2/en active Active
- 2021-09-07 ZA ZA2021/06581A patent/ZA202106581B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021015137A2 (pt) | 2021-09-28 |
| IL285560B1 (en) | 2023-12-01 |
| EP3923911A4 (en) | 2022-11-09 |
| EP3923911C0 (en) | 2023-07-12 |
| ES2952251T3 (es) | 2023-10-30 |
| RS64618B1 (sr) | 2023-10-31 |
| IL285560A (en) | 2021-09-30 |
| KR20210126665A (ko) | 2021-10-20 |
| PL3923911T3 (pl) | 2023-12-27 |
| AU2020220895A1 (en) | 2021-08-12 |
| KR102534457B1 (ko) | 2023-05-18 |
| US20210346389A1 (en) | 2021-11-11 |
| MX2021009535A (es) | 2022-10-10 |
| EP3923911A1 (en) | 2021-12-22 |
| HUE063091T2 (hu) | 2024-01-28 |
| ZA202106581B (en) | 2022-09-28 |
| CA3127175A1 (en) | 2020-08-20 |
| CA3127175C (en) | 2023-06-27 |
| AU2020220895B9 (en) | 2023-02-02 |
| US11439648B2 (en) | 2022-09-13 |
| IL285560B2 (en) | 2024-04-01 |
| EP3923911B1 (en) | 2023-07-12 |
| AU2020220895B2 (en) | 2022-11-17 |
| JP2022519675A (ja) | 2022-03-24 |
| CN113382717A (zh) | 2021-09-10 |
| WO2020165755A1 (en) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011116787A5 (cg-RX-API-DMAC7.html) | ||
| RU2014152445A (ru) | Композиции на основе диклофенака | |
| JP2025168479A (ja) | 外用組成物、及び外用組成物におけるヘパリン類似物質の安定化方法 | |
| RU2015149680A (ru) | Агенты для подавления активности и/или снижения количества bcl-xl и/или bcl-w | |
| BR112012029959A2 (pt) | compostos de carbamato de mentila como ativos para clareamento de pele e/ou cabelo | |
| RU2010107892A (ru) | Производные феноксипирролидина, их применение и фармацевтические композиции, содержащие их | |
| JP2015522049A5 (cg-RX-API-DMAC7.html) | ||
| MX2013003695A (es) | Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida. | |
| JP2018537503A (ja) | 末梢神経障害を治療するための方法及び組成物 | |
| JP2022519675A5 (cg-RX-API-DMAC7.html) | ||
| PH12022552727A1 (en) | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE | |
| MX2007000967A (es) | Composiciones de risedronato y metodos para su uso. | |
| US11439648B2 (en) | Use of topical BRAF inhibitor compositions for treatment of radiation dermatitis | |
| HK1203394A1 (en) | Ghrelin receptor agonists for the treatment of achlorhydria | |
| MX2022005014A (es) | Combinacion de un antagonista de cxcr7 con un modulador del receptor s1p1. | |
| JP2015081244A (ja) | ニキビ治療用医薬組成物 | |
| RU2005132004A (ru) | Стабилизированные композиции для местного применения, содержащие кетопрофен | |
| TWI712408B (zh) | 外用醫藥組成物 | |
| RU2021126784A (ru) | Применение композиций на основе ингибитора braf для наружнего применения для лечения лучевого дерматита | |
| AU2004281521A1 (en) | Topical compositions comprising telmesteine for treating dermatological disorders | |
| JP3338877B2 (ja) | 掻痒性皮膚疾患用噴霧剤 | |
| CA2489705A1 (en) | Use of amide derivative of ge 2270 factor a3 for the treatment of acne | |
| JP7271163B2 (ja) | 外用組成物 | |
| NZ606177A (en) | Compositions for the treatment of actinic keratosis | |
| EA201591218A1 (ru) | Способы и композиции для введения оксибутинина |